
## Juergen Siepmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1944339/publications.pdf Version: 2024-02-01



LIEDCEN SIEDMANN

#	Article	lF	CITATIONS
1	Clinical translation of advanced colonic drug delivery technologies. Advanced Drug Delivery Reviews, 2022, 181, 114076.	6.6	51
2	Pharmaceutical Technology in Europe. International Journal of Pharmaceutics, 2022, 613, 121441.	2.6	0
3	How agarose gels surrounding PLGA implants limit swelling and slow down drug release. Journal of Controlled Release, 2022, 343, 255-266.	4.8	18
4	Hot melt extruded PLGA implants loaded with ibuprofen: How heat exposure alters the physical drug state. Journal of Drug Delivery Science and Technology, 2022, 73, 103432.	1.4	7
5	PLGA implants for controlled drug release: Impact of the diameter. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 50-60.	2.0	10
6	PEO hot melt extrudates for controlled drug delivery: Importance of the type of drug and loading. Journal of Drug Delivery Science and Technology, 2021, 61, 102238.	1.4	4
7	Extracellular Vesicles and Biomaterial Design: New Therapies for Cardiac Repair. Trends in Molecular Medicine, 2021, 27, 231-247.	3.5	31
8	Starch-based controlled release matrix tablets: Impact of the type of starch. Journal of Drug Delivery Science and Technology, 2021, 61, 102152.	1.4	14
9	Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Monolithic dispersions studied at lower temperatures. International Journal of Pharmaceutics, 2021, 596, 120220.	2.6	13
10	Evaluation of the Efficacy of Dexamethasone-Eluting Electrode Array on the Post-Implant Cochlear Fibrotic Reaction by Three-Dimensional Immunofluorescence Analysis in Mongolian Gerbil Cochlea. Journal of Clinical Medicine, 2021, 10, 3315.	1.0	9
11	Injection-molded capsule bodies and caps based on polymer blends for controlled drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 1-14.	2.0	4
12	Dexamethasone-loaded cochlear implants: How to provide a desired "burst release― International Journal of Pharmaceutics: X, 2021, 3, 100088.	1.2	6
13	Towards a Better Understanding of Verapamil Release from Kollicoat SR:IR Coated Pellets Using Non-Invasive Analytical Tools. Pharmaceutics, 2021, 13, 1723.	2.0	3
14	Oral colon delivery platform based on a novel combination approach: Design concept and preliminary evaluation. Journal of Drug Delivery Science and Technology, 2021, 66, 102919.	1.4	7
15	GnRH neurons recruit astrocytes in infancy to facilitate network integration and sexual maturation. Nature Neuroscience, 2021, 24, 1660-1672.	7.1	25
16	Sink conditions do not guarantee the absence of saturation effects. International Journal of Pharmaceutics, 2020, 577, 119009.	2.6	34
17	Towards a better understanding of the release mechanisms of caffeine from PLGA microparticles. Journal of Applied Polymer Science, 2020, 137, 48710.	1.3	14
18	A Warm Welcome to Leena Peltonen as Editor for Europe, Africa and Near East. International Journal of Pharmaceutics, 2020, 587, 119720.	2.6	0

#	Article	IF	CITATIONS
19	In-situ forming implants for dual controlled release of chlorhexidine and ibuprofen for periodontitis treatment: Microbiological and mechanical key properties. Journal of Drug Delivery Science and Technology, 2020, 60, 101956.	1.4	12
20	Robustness of Controlled Release Tablets Based on a Cross-linked Pregelatinized Potato Starch Matrix. AAPS PharmSciTech, 2020, 21, 148.	1.5	6
21	Injection Molded Capsules for Colon Delivery Combining Time-Controlled and Enzyme-Triggered Approaches. International Journal of Molecular Sciences, 2020, 21, 1917.	1.8	13
22	Eudragit RL-based film coatings: How to minimize sticking and adjust drug release using MAS. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 148, 126-133.	2.0	8
23	Poorly soluble drugs. International Journal of Pharmaceutics, 2020, 577, 119055.	2.6	2
24	Sincere thanks to Véronique Préat and Thorsteinn Loftsson and a Warm Welcome to Carmen Alvarez-Lorenzo and Juan Manuel Irache. International Journal of Pharmaceutics, 2020, 576, 119056.	2.6	0
25	In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: Proof of concept study in vivo. International Journal of Pharmaceutics, 2019, 569, 118564.	2.6	25
26	Coloring of PLGA implants to better understand the underlying drug release mechanisms. International Journal of Pharmaceutics, 2019, 569, 118563.	2.6	12
27	In-situ forming PLGA implants: How additives affect swelling and drug release. Journal of Drug Delivery Science and Technology, 2019, 53, 101180.	1.4	10
28	Hot melt extruded polysaccharide blends for controlled drug delivery. Journal of Drug Delivery Science and Technology, 2019, 54, 101317.	1.4	5
29	Often neglected: PLGA/PLA swelling orchestrates drug release: HME implants. Journal of Controlled Release, 2019, 306, 97-107.	4.8	77
30	Controlled release tablets based on HPMC:lactose blends. Journal of Drug Delivery Science and Technology, 2019, 52, 607-617.	1.4	13
31	Mechanistic explanation of the (up to) 3 release phases of PLGA microparticles: Diprophylline dispersions. International Journal of Pharmaceutics, 2019, 572, 118819.	2.6	23
32	Lipids and polymers in pharmaceutical technology: Lifelong companions. International Journal of Pharmaceutics, 2019, 558, 128-142.	2.6	101
33	Hybrid Ear Cubes for local controlled dexamethasone delivery to the inner ear. European Journal of Pharmaceutical Sciences, 2019, 126, 23-32.	1.9	12
34	IJP's Editor for the Americas, Australia and New Zealand. International Journal of Pharmaceutics, 2018, 535, iii.	2.6	0
35	Using Milling To Explore Physical States: The Amorphous and Polymorphic Forms of Dexamethasone. Crystal Growth and Design, 2018, 18, 1748-1757.	1.4	32
36	When drugs plasticize film coatings: Unusual formulation effects observed with metoprolol and Eudragit RS. International Journal of Pharmaceutics, 2018, 539, 39-49.	2.6	5

#	Article	IF	CITATIONS
37	Crystalline Polymorphism Emerging From a Milling-Induced Amorphous Form: The Case of Chlorhexidine Dihydrochloride. Journal of Pharmaceutical Sciences, 2018, 107, 121-126.	1.6	16
38	In-situ forming PLGA implants for intraocular dexamethasone delivery. International Journal of Pharmaceutics, 2018, 548, 337-348.	2.6	52
39	Implant cochléaire et implant auditif central. , 2018, , 115-154.		Ο
40	Physical key properties of antibiotic-free, PLGA/HPMC-based in-situ forming implants for local periodontitis treatment. International Journal of Pharmaceutics, 2017, 521, 282-293.	2.6	26
41	PLCA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release. Journal of Controlled Release, 2017, 253, 19-29.	4.8	38
42	Limited drug solubility can be decisive even for freely soluble drugs in highly swollen matrix tablets. International Journal of Pharmaceutics, 2017, 526, 280-290.	2.6	22
43	In vitro and in vivo behavior of ground tadalafil hot-melt extrudates: How the carrier material can effectively assure rapid or controlled drug release. International Journal of Pharmaceutics, 2017, 528, 498-510.	2.6	23
44	Chitosan-clay nanocomposite microparticles for controlled drug delivery: Effects of the MAS content and TPP crosslinking. Journal of Drug Delivery Science and Technology, 2017, 40, 1-10.	1.4	37
45	Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis. International Journal of Pharmaceutics, 2017, 533, 26-33.	2.6	9
46	Novel insights into controlled drug release from coated pellets by confocal Raman microscopy. Journal of Raman Spectroscopy, 2016, 47, 757-762.	1.2	11
47	How to adjust dexamethasone mobility in silicone matrices: A quantitative treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 27-37.	2.0	11
48	Ear Cubes for local controlled drug delivery to the inner ear. International Journal of Pharmaceutics, 2016, 509, 85-94.	2.6	21
49	PEO hot melt extrudates for controlled drug delivery: Importance of the molecular weight. Journal of Drug Delivery Science and Technology, 2016, 36, 130-140.	1.4	24
50	Towards a better understanding of the different release phases from PLGA microparticles: Dexamethasone-loaded systems. International Journal of Pharmaceutics, 2016, 514, 189-199.	2.6	71
51	Importance of air bubbles in the core of coated pellets: Synchrotron X-ray microtomography allows for new insights. Journal of Controlled Release, 2016, 237, 125-137.	4.8	12
52	Professor Alexander T. Florence: An exceptional scientist and man. International Journal of Pharmaceutics, 2016, 514, 1-2.	2.6	2
53	Gentamicin-loaded poly(lactic-co-glycolic acid) microparticles for the prevention of maxillofacial and orthopedic implant infections. Materials Science and Engineering C, 2016, 64, 108-116.	3.8	27
54	In vitro release studies of insulin from lipid implants in solution and in a hydrogel matrix mimicking the subcutis. European Journal of Pharmaceutical Sciences, 2016, 81, 103-112.	1.9	30

#	Article	IF	CITATIONS
55	Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear. Otology and Neurotology, 2015, 36, 1572-1579.	0.7	25
56	Mechanistic analysis of PLGA/HPMC-based in-situ forming implants for periodontitis treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 273-283.	2.0	34
57	Quaternary polymethacrylate–magnesium aluminum silicate films: Water uptake kinetics and film permeability. International Journal of Pharmaceutics, 2015, 490, 165-172.	2.6	10
58	Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration. Drug Development and Industrial Pharmacy, 2015, 41, 2037-2044.	0.9	29
59	Dexamethasone eluting electrodes for cochlear implantation: Effect on residual hearing. Cochlear Implants International, 2015, 16, 195-200.	0.5	48
60	Special JDDST issue in honour of Prof. Dominique Duchêne. Journal of Drug Delivery Science and Technology, 2015, 30, 251-259.	1.4	0
61	Controlled delivery of a new broad spectrum antibacterial agent against colitis: In vitro and in vivo performance. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 152-161.	2.0	13
62	Preparation of polymeric fenofibrate formulations with accelerated drug release: Solvent evaporation versus co-grinding. Journal of Drug Delivery Science and Technology, 2015, 30, 397-407.	1.4	8
63	Does PLGA microparticle swelling control drug release? New insight based on single particle swelling studies. Journal of Controlled Release, 2015, 213, 120-127.	4.8	80
64	In-situ forming composite implants for periodontitis treatment: How the formulation determines system performance. International Journal of Pharmaceutics, 2015, 486, 38-51.	2.6	35
65	Importance of PLGA microparticle swelling for the control of prilocaine release. Journal of Drug Delivery Science and Technology, 2015, 30, 123-132.	1.4	35
66	Fatty acids for controlled release applications: A comparison between prilling and solid lipid extrusion as manufacturing techniques. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 173-184.	2.0	12
67	In vivo efficacy of microbiota-sensitive coatings for colon targeting: A promising tool for IBD therapy. Journal of Controlled Release, 2015, 197, 121-130.	4.8	34
68	How to easily provide zero order release of freely soluble drugs from coated pellets. International Journal of Pharmaceutics, 2015, 478, 31-38.	2.6	20
69	Accelerated ketoprofen release from spray-dried polymeric particles: importance of phase transitions and excipient distribution. Drug Development and Industrial Pharmacy, 2015, 41, 838-850.	0.9	4
70	Accelerated fenofibrate release from spray-dried microparticles based on polymer blends. Journal of Drug Delivery Science and Technology, 2014, 24, 185-190.	1.4	2
71	Mechanisms Controlling Theophylline Release from Ethanol-Resistant Coated Pellets. Pharmaceutical Research, 2014, 31, 731-741.	1.7	9
72	In silico simulation of niacin release from lipid tablets: Theoretical predictions and independent experiments. Journal of Controlled Release, 2014, 175, 63-71.	4.8	7

#	Article	IF	CITATIONS
73	In situ forming implants for periodontitis treatment with improved adhesive properties. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 342-350.	2.0	60
74	PLGAs bearing carboxylated side chains: Novel matrix formers with improved properties for controlled drug delivery. Journal of Controlled Release, 2013, 166, 256-267.	4.8	14
75	Predicting drug release from HPMC/lactose tablets. International Journal of Pharmaceutics, 2013, 441, 826-834.	2.6	26
76	In-silico simulations of advanced drug delivery systems: What will the future offer?. International Journal of Pharmaceutics, 2013, 454, 512-516.	2.6	14
77	PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine. International Journal of Pharmaceutics, 2013, 443, 68-79.	2.6	31
78	Application of terahertz pulsed imaging to analyse film coating characteristics of sustained-release coated pellets. International Journal of Pharmaceutics, 2013, 457, 521-526.	2.6	41
79	For the special IJP issue "Poorly soluble drugs― International Journal of Pharmaceutics, 2013, 453, 1-2.	2.6	15
80	Analysis of Bulk and Hydration Water During Thermal Lysozyme Denaturation Using Raman Scattering. Food Biophysics, 2013, 8, 170-176.	1.4	14
81	Accelerated ketoprofen release from polymeric matrices: Importance of the homogeneity/heterogeneity of excipient distribution. International Journal of Pharmaceutics, 2013, 457, 298-307.	2.6	17
82	Stability of aqueous polymeric controlled release film coatings. International Journal of Pharmaceutics, 2013, 457, 437-445.	2.6	35
83	Characterization and optimization of GMO-based gels with long term release for intraarticular administration. International Journal of Pharmaceutics, 2013, 451, 95-103.	2.6	26
84	Progress in film coating. International Journal of Pharmaceutics, 2013, 457, 361.	2.6	5
85	Quaternary polymethacrylate–magnesium aluminum silicate films: Molecular interactions, mechanical properties and tackiness. International Journal of Pharmaceutics, 2013, 458, 57-64.	2.6	18
86	Ethanol-resistant ethylcellulose/guar gum coatings – Importance of formulation parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1250-1258.	2.0	12
87	Mathematical modeling of drug dissolution. International Journal of Pharmaceutics, 2013, 453, 12-24.	2.6	338
88	Ethanol-resistant polymeric film coatings for controlled drug delivery. Journal of Controlled Release, 2013, 169, 1-9.	4.8	35
89	Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 2012, 64, 163-174.	6.6	661
90	Development and evaluation of sustained-release clonidine-loaded PLGA microparticles. International Journal of Pharmaceutics, 2012, 437, 20-28.	2.6	58

#	Article	IF	CITATIONS
91	Comparative study of vascular prostheses coated with polycyclodextrins for controlled ciprofloxacin release. Carbohydrate Polymers, 2012, 90, 1695-1703.	5.1	41
92	Drug release from extruded solid lipid matrices: Theoretical predictions and independent experiments. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 122-129.	2.0	18
93	Zinc–alginate microparticles for controlled pulmonary delivery of proteins prepared by spray-drying. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 121-130.	2.0	48
94	Sustained release from hot-melt extruded matrices based on ethylene vinyl acetate and polyethylene oxide. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 526-533.	2.0	38
95	Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 68-83.	2.9	69
96	Diffusion Controlled Drug Delivery Systems. , 2012, , 127-152.		14
97	Swelling Controlled Drug Delivery Systems. , 2012, , 153-170.		8
98	How Strongly Does Trehalose Interact with Lysozyme in the Solid State? Insights from Molecular Dynamics Simulation and Inelastic Neutron Scattering. Journal of Physical Chemistry B, 2012, 116, 11103-11116.	1.2	58
99	Impact of the experimental conditions on drug release from parenteral depot systems: From negligible to significant. International Journal of Pharmaceutics, 2012, 432, 11-22.	2.6	18
100	Novel preparation techniques for alginate–poloxamer microparticles controlling protein release on mucosal surfaces. European Journal of Pharmaceutical Sciences, 2012, 45, 358-366.	1.9	48
101	Cubic phase-forming dry powders for controlled drug delivery on mucosal surfaces. Journal of Controlled Release, 2012, 157, 206-215.	4.8	25
102	Modeling of diffusion controlled drug delivery. Journal of Controlled Release, 2012, 161, 351-362.	4.8	641
103	Predictability of drug release from cochlear implants. Journal of Controlled Release, 2012, 159, 60-68.	4.8	43
104	MALDI-TOF MS imaging of controlled release implants. Journal of Controlled Release, 2012, 161, 98-108.	4.8	27
105	Dynamic and static curing of ethylcellulose:PVA–PEG graft copolymer film coatings. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 455-461.	2.0	24
106	Drug release mechanisms of cast lipid implants. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 394-400.	2.0	31
107	Higuchi equation: Derivation, applications, use and misuse. International Journal of Pharmaceutics, 2011, 418, 6-12.	2.6	719
108	Mathematical modeling of drug release from lipid dosage forms. International Journal of Pharmaceutics, 2011, 418, 42-53.	2.6	64

#	Article	IF	CITATIONS
109	In honor of Takeru Higuchi. International Journal of Pharmaceutics, 2011, 418, 1-2.	2.6	6
110	Controlled release implants based on cast lipid blends. European Journal of Pharmaceutical Sciences, 2011, 43, 78-83.	1.9	24
111	Cast Lipid Implants for Controlled Drug Delivery: Importance of the Tempering Conditions. Journal of Pharmaceutical Sciences, 2011, 100, 3471-3481.	1.6	16
112	Peas starchâ€based film coatings for siteâ€specific drug delivery to the colon. Journal of Applied Polymer Science, 2011, 119, 1176-1184.	1.3	18
113	Methyl-β-cyclodextrin modified vascular prosthesis: Influence of the modification level on the drug delivery properties in different media. Acta Biomaterialia, 2011, 7, 304-314.	4.1	43
114	Drug release mechanisms of compressed lipid implants. International Journal of Pharmaceutics, 2011, 404, 27-35.	2.6	40
115	Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles. International Journal of Pharmaceutics, 2011, 404, 75-82.	2.6	37
116	Drug release mechanisms from Kollicoat SR:Eudragit NE coated pellets. International Journal of Pharmaceutics, 2011, 409, 30-37.	2.6	38
117	Preparation and characterization of poly(lactic-co-glycolic acid) microspheres loaded with a labile antiparkinson prodrug. International Journal of Pharmaceutics, 2011, 409, 289-296.	2.6	34
118	Simultaneous controlled vitamin release from multiparticulates: Theory and experiment. International Journal of Pharmaceutics, 2011, 412, 68-76.	2.6	17
119	Non-coated multiparticulate matrix systems for colon targeting. Drug Development and Industrial Pharmacy, 2011, 37, 1150-1159.	0.9	15
120	Drug release from PLGA-based microparticles: Effects of the "microparticle:bulk fluid―ratio. International Journal of Pharmaceutics, 2010, 383, 123-131.	2.6	66
121	Modeling drug release from PVAc/PVP matrix tablets. Journal of Controlled Release, 2010, 141, 216-222.	4.8	59
122	Deeper insight into the drug release mechanisms in Eudragit RL-based delivery systems. International Journal of Pharmaceutics, 2010, 389, 139-146.	2.6	30
123	Bone implants modified with cyclodextrin: Study of drug release in bulk fluid and into agarose gel. International Journal of Pharmaceutics, 2010, 400, 74-85.	2.6	57
124	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. Journal of Drug Delivery Science and Technology, 2010, 20, 193-199.	1.4	10
125	Simulated food effects on drug release from ethylcellulose: PVA–PEG graft copolymer-coated pellets. Drug Development and Industrial Pharmacy, 2010, 36, 173-179.	0.9	7
126	Influence of urea and guanidine hydrochloride on lysozyme stability and thermal denaturation; a correlation between activity, protein dynamics and conformational changes. Physical Chemistry Chemical Physics, 2010, 12, 13189.	1.3	73

#	Article	IF	CITATIONS
127	Curing of aqueous polymeric film coatings: Importance of the coating level and type of plasticizer. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 362-370.	2.0	60
128	Enzymatically degraded Eurylon 6 HP-PC: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. Journal of Pharmacy and Pharmacology, 2010, 62, 1676-1684.	1.2	18
129	Characterization of ethylcellulose: starch-based film coatings for colon targeting. Drug Development and Industrial Pharmacy, 2009, 35, 1190-1200.	0.9	15
130	Prediction of drug release from ethylcellulose coated pellets. Journal of Controlled Release, 2009, 135, 71-79.	4.8	77
131	Fenofibrate-loaded PLGA microparticles: Effects on ischemic stroke. European Journal of Pharmaceutical Sciences, 2009, 37, 43-52.	1.9	14
132	Development of injection moulded matrix tablets based on mixtures of ethylcellulose and low-substituted hydroxypropylcellulose. European Journal of Pharmaceutical Sciences, 2009, 37, 207-216.	1.9	58
133	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. European Journal of Pharmaceutical Sciences, 2009, 37, 427-433.	1.9	56
134	Characterization of Moistureâ€Protective Polymer Coatings Using Differential Scanning Calorimetry and Dynamic Vapor Sorption. Journal of Pharmaceutical Sciences, 2009, 98, 651-664.	1.6	35
135	Towards More Realistic In Vitro Release Measurement Techniques for Biodegradable Microparticles. Pharmaceutical Research, 2009, 26, 691-699.	1.7	39
136	Improved long term stability of aqueous ethylcellulose film coatings: Importance of the type of drug and starter core. International Journal of Pharmaceutics, 2009, 368, 138-145.	2.6	29
137	Novel polymeric film coatings for colon targeting: How to adjust desired membrane properties. International Journal of Pharmaceutics, 2009, 371, 64-70.	2.6	25
138	Protection of moisture-sensitive drugs with aqueous polymer coatings: Importance of coating and curing conditions. International Journal of Pharmaceutics, 2009, 378, 59-65.	2.6	32
139	Effects of film coating thickness and drug layer uniformity on in vitro drug release from sustained-release coated pellets: A case study using terahertz pulsed imaging. International Journal of Pharmaceutics, 2009, 382, 151-159.	2.6	53
140	Announcing the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. AAPS PharmSciTech, 2009, 10, 806.	1.5	0
141	Alginate–poloxamer microparticles for controlled drug delivery to mucosal tissue. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 42-53.	2.0	74
142	Drug release mechanisms from ethylcellulose: PVA-PEG graft copolymer-coated pellets. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 130-137.	2.0	55
143	Colon targeting with bacteria-sensitive films adapted to the disease state. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 74-81.	2.0	31
144	Importance of glassy-to-rubbery state transitions in moisture-protective polymer coatings. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 146-153.	2.0	16

#	Article	IF	CITATIONS
145	Drug release from MCC- and carrageenan-based pellets: Experiment and theory. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 302-309.	2.0	46
146	Modeling drug release from hot-melt extruded mini-matrices with constant and non-constant diffusivities. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 292-301.	2.0	20
147	Characterisation of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 366-372.	2.0	23
148	Porous pellets as drug delivery system. Drug Development and Industrial Pharmacy, 2009, 35, 655-662.	0.9	18
149	PLGA-based drug delivery systems: Importance of the type of drug and device geometry. International Journal of Pharmaceutics, 2008, 354, 95-103.	2.6	215
150	Mathematical modeling of drug delivery. International Journal of Pharmaceutics, 2008, 364, 328-343.	2.6	1,036
151	Future perspectives in pharmaceutics: contributions from younger scientists. Preface. International Journal of Pharmaceutics, 2008, 364, 157-158.	2.6	1
152	Polymer blends for controlled release coatings. Journal of Controlled Release, 2008, 125, 1-15.	4.8	267
153	How to improve the storage stability of aqueous polymeric film coatings. Journal of Controlled Release, 2008, 126, 26-33.	4.8	46
154	A novel mathematical model quantifying drug release from lipid implants. Journal of Controlled Release, 2008, 128, 233-240.	4.8	32
155	Lipid implants as drug delivery systems. Expert Opinion on Drug Delivery, 2008, 5, 291-307.	2.4	33
156	pH-sensitive film coatings: Towards a better understanding and facilitated optimization. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 2-10.	2.0	29
157	The Modified-Release Drug Delivery Landscape. , 2008, , 17-34.		2
158	Cross-linking of chitosan and chitosan/poly(ethylene oxide) beads: A theoretical treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 339-348.	2.0	51
159	Carrageenan as an Efficient Drug Release Modifier for Ethylcellulose-Coated Pharmaceutical Dosage Forms. Biomacromolecules, 2007, 8, 3984-3991.	2.6	16
160	Mechanisms controlling protein release from lipidic implants: Effects of PEG addition. Journal of Controlled Release, 2007, 118, 161-168.	4.8	63
161	How to adjust desired drug release patterns from ethylcellulose-coated dosage forms. Journal of Controlled Release, 2007, 119, 182-189.	4.8	93
162	Recombinant gelatin hydrogels for the sustained release of proteins. Journal of Controlled Release, 2007, 119, 301-312.	4.8	112

#	Article	IF	CITATIONS
163	New Insight into the Role of Polyethylene Glycol Acting as Protein Release Modifier in Lipidic Implants. Pharmaceutical Research, 2007, 24, 1527-1537.	1.7	35
164	Microparticles Used as Drug Delivery Systems. , 2006, , 15-21.		48
165	Drug delivery to the upper small intestine window using gastroretentive technologies. Current Opinion in Pharmacology, 2006, 6, 501-508.	1.7	193
166	Aqueous HPMCAS coatings: Effects of formulation and processing parameters on drug release and mass transport mechanisms. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 63, 262-269.	2.0	38
167	Local controlled drug delivery to the brain: Mathematical modeling of the underlying mass transport mechanisms. International Journal of Pharmaceutics, 2006, 314, 101-119.	2.6	76
168	Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: Preparation and physicochemical characterization. International Journal of Pharmaceutics, 2006, 314, 127-136.	2.6	77
169	Effects of the type of release medium on drug release from PLGA-based microparticles: Experiment and theory. International Journal of Pharmaceutics, 2006, 314, 189-197.	2.6	141
170	How porosity and size affect the drug release mechanisms from PLGA-based microparticles. International Journal of Pharmaceutics, 2006, 314, 198-206.	2.6	287
171	Drug release from lipid-based implants: Elucidation of the underlying mass transport mechanisms. International Journal of Pharmaceutics, 2006, 314, 137-144.	2.6	66
172	Programmable implants—From pulsatile to controlled release. International Journal of Pharmaceutics, 2006, 314, 161-169.	2.6	23
173	Controlled drug release from Gelucire-based matrix pellets: Experiment and theory. International Journal of Pharmaceutics, 2006, 317, 136-143.	2.6	44
174	Key parameters affecting the initial release (burst) and encapsulation efficiency of peptide-containing poly(lactide-co-glycolide) microparticles. International Journal of Pharmaceutics, 2006, 324, 168-175.	2.6	77
175	Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 2006, 3, 217-233.	2.4	212
176	Sustained release of nanosized complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery. Journal of Controlled Release, 2006, 112, 369-381.	4.8	93
177	Drugs acting as plasticizers in polymeric systems: A quantitative treatment. Journal of Controlled Release, 2006, 115, 298-306.	4.8	87
178	Microparticles Used as Drug Delivery Systems. , 2006, , 15-21.		2
179	Blends of aqueous polymer dispersions used for pellet coating: Importance of the particle size. Journal of Controlled Release, 2005, 105, 226-239.	4.8	61
180	Mobility of model proteins in hydrogels composed of oppositely charged dextran microspheres studied by protein release and fluorescence recovery after photobleaching. Journal of Controlled Release, 2005, 110, 67-78.	4.8	70

#	Article	lF	CITATIONS
181	pH-Sensitive Polymer Blends Used as Coating Materials to Control Drug Release from Spherical Beads: Elucidation of the Underlying Mass Transport Mechanisms. Pharmaceutical Research, 2005, 22, 1129-1141.	1.7	72
182	How Autocatalysis Accelerates Drug Release from PLGA-Based Microparticles:Â A Quantitative Treatment. Biomacromolecules, 2005, 6, 2312-2319.	2.6	257
183	pH-Sensitive Polymer Blends used as Coating Materials to Control Drug Release from Spherical Beads:Â Importance of the Type of Core. Biomacromolecules, 2005, 6, 2074-2083.	2.6	40
184	Effect of the size of biodegradable microparticles on drug release: experiment and theory. Journal of Controlled Release, 2004, 96, 123-134.	4.8	234
185	Polymer blends used for the aqueous coating of solid dosage forms: importance of the type of plasticizer. Journal of Controlled Release, 2004, 99, 1-13.	4.8	105
186	Polymer Blends Used for the Coating of Multiparticulates: Comparison of Aqueous and Organic Coating Techniques. Pharmaceutical Research, 2004, 21, 882-890.	1.7	107
187	Effect of the size of biodegradable microparticles on drug release: experiment and theory. Journal of Controlled Release, 2004, 96, 123-123.	4.8	161
188	Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. European Journal of Pharmaceutical Sciences, 2003, 18, 37-45.	1.9	158
189	Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. Journal of Controlled Release, 2003, 88, 413-428.	4.8	73
190	Blends of enteric and GIT-insoluble polymers used for film coating: physicochemical characterization and drug release patterns. Journal of Controlled Release, 2003, 89, 457-471.	4.8	120
191	Multiple unit gastroretentive drug delivery systems: A new preparation method for low density microparticles. Journal of Microencapsulation, 2003, 20, 329-347.	1.2	70
192	Pharmaceutical Applications of Shellac: Moisture-Protective and Taste-Masking Coatings and Extended-Release Matrix Tablets. Drug Development and Industrial Pharmacy, 2003, 29, 925-938.	0.9	98
193	Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 271-279.	2.0	78
194	Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. Journal of Microencapsulation, 2003, 20, 329-47.	1.2	37
195	PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. European Journal of Pharmaceutical Sciences, 2002, 15, 355-366.	1.9	297
196	Floating microparticles based on low density foam powder. International Journal of Pharmaceutics, 2002, 241, 279-292.	2.6	135
197	The effect of gamma-irradiation on drug release from bioerodible microparticles: a quantitative treatment. International Journal of Pharmaceutics, 2002, 242, 281-284.	2.6	45
198	Understanding and predicting drug delivery from hydrophilic matrix tablets using the "sequential layer" model. Pharmaceutical Research, 2002, 19, 306-314.	1.7	123

#	Article	IF	CITATIONS
199	A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations. Pharmaceutical Research, 2002, 19, 1885-1893.	1.7	146
200	Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 51, 17-24.	2.0	10
201	Mathematical modeling of controlled drug delivery. Advanced Drug Delivery Reviews, 2001, 48, 137-138.	6.6	80
202	Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews, 2001, 48, 139-157.	6.6	1,882
203	Mathematical modeling of bioerodible, polymeric drug delivery systems. Advanced Drug Delivery Reviews, 2001, 48, 229-247.	6.6	651
204	Calculation of the required size and shape of hydroxypropyl methylcellulose matrices to achieve desired drug release profiles. International Journal of Pharmaceutics, 2000, 201, 151-164.	2.6	125
205	pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. Journal of Controlled Release, 2000, 67, 101-110.	4.8	154
206	Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design. Journal of Controlled Release, 2000, 69, 455-468.	4.8	89
207	Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model). Pharmaceutical Research, 2000, 17, 1290-1298.	1.7	189
208	A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets. Journal of Pharmaceutical Sciences, 1999, 88, 65-72.	1.6	153
209	HPMC-matrices for controlled drug delivery: a new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharmaceutical Research, 1999, 16, 1748-1756.	1.7	288
210	Diffusion-controlled drug delivery systems: calculation of the required composition to achieve desired release profiles. Journal of Controlled Release, 1999, 60, 379-389.	4.8	146
211	Calculation of the Dimensions of Drug-Polymer Devices Based on Diffusion Parameters. Journal of Pharmaceutical Sciences, 1998, 87, 827-832.	1.6	67
212	Modeling plasticizer uptake in aqueous polymer dispersions. International Journal of Pharmaceutics, 1998, 165, 191-200.	2.6	32